TriSalus Life Sciences reaffirms $60M-$62M revenue guidance for 2026 while expanding PEDD portfolio
Source: SeekingAlpha
2026-03-05 18:26:38 ET
More on TriSalus Life Sciences
- TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
- TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
- TriSalus Life Sciences GAAP EPS of -$0.21 misses by $0.07, revenue of $13.2M in-line
- TriSalus prices $40 mln public stock offering
- Seeking Alpha’s Quant Rating on TriSalus Life Sciences
Read the full article on Seeking Alpha
For further details see:
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
TriSalus Life Sciences Inc. Warrant
NASDAQ: TLSIW
TLSIW Trading
-1.27% G/L:
$1.56 Last:
1,306 Volume:
$1.58 Open:
TLSIW Latest News
TLSIW Stock Data
$218,310,730
36,224,125
N/A
18
N/A
Medical Equipment & Supplies
Healthcare
US
Westminster
